SER
Serina Therapeutics, Inc.2.9200
-0.0700-2.34%
Dec 16, 3:54:32 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
31.14MP/E (TTM)
-Basic EPS (TTM)
-1.87Dividend Yield
0%Recent Filings
8-K
FDA clears SER-252 IND
Serina Therapeutics secured FDA clearance for its IND on SER-252, an investigational apomorphine therapy for advanced Parkinson's, on January 27, 2026. This greenlights regulatory and site activities for a planned Phase 1b registrational study under a 505(b)(2) NDA pathway. FDA IND clearance unlocks the pipeline. Preclinical data suggest continuous stimulation without skin reactions, though trials carry inherent risks.
8-K
NYSE equity deficiency notice
Serina Therapeutics received an NYSE American deficiency notice on January 9, 2026, for stockholders' equity of $1.6 million as of September 30, 2025—below the $4.0 million threshold amid losses in three of four recent fiscal years. It must submit a compliance plan by February 8, 2026, targeting standards by July 9, 2027. Shares trade on; delisting looms if rejected. No business operations affected.
8-K
SER-252 hold response submitted
Serina Therapeutics submitted a complete response on December 9, 2025, to the FDA's November 25 clinical hold letter on its SER-252 IND for advanced Parkinson's, addressing trehalose excipient concerns without impacting the apomorphine drug or enFuse device. Site start-ups continue globally; first-patient-in for the Phase 1b study targets Q1 2026, pending hold lift. Dosing awaits FDA resolution.
10-Q
Q3 FY2025 results
Serina Therapeutics posted a $6.4M operating loss for Q3 ended September 30, 2025, up 20% y/y from $5.3M (derived), driven by R&D spend on SER-252 that doubled to $3.7M amid clinical prep. Net loss narrowed to $4.6M from a $1.4M profit, as warrant fair-value gains fell to $1.0M from $6.7M y/y while a $0.7M expiration gain helped. Cash climbed to $8.6M after $17M in financing including $4.9M Series A preferred and $4.9M from a $20M convertible note's first tranche (10% rate, 5-year term, $5.18/share conversion). Cash burn eased to $11.9M YTD. FDA placed a clinical hold on SER-252 IND over an excipient, unrelated to the active drug.
8-K
Q3 loss; SER-252 FDA hold
Serina Therapeutics reported Q3 net loss of $4.6M on $6.4M operating expenses, up from $5.3M last year, with cash at $8.6M. FDA backed SER-252's 505(b)(2) pathway for Parkinson's yet imposed IND clinical hold over an excipient on November 3. Funding secured: $5M initial from $20M convertible note; $2.8M net from ATM shares. Hold delays registrational study.
IPO
Employees
Sector
Industry
ATHE
Alterity Therapeutics Limited
3.07+0.06
CGTX
Cognition Therapeutics, Inc.
1.52-0.08
MCRB
Seres Therapeutics, Inc.
16.20+0.30
NERV
Minerva Neurosciences, Inc
4.17+0.13
NRSN
NeuroSense Therapeutics Ltd.
0.85+0.01
OSRH
OSR Holdings, Inc.
0.55-0.02
SAVA
Cassava Sciences, Inc.
2.93+0.13
SEOVF
SERNOVA BIOTHERAPEUTICS INC.
0.10+0.00
SLNO
Soleno Therapeutics, Inc.
49.50-0.45
SMNR
Semnur Pharmaceuticals Inc.
9.00+0.00